部份中文硬脂酸红霉素处方资料（仅供参考）
中文名称: 硬脂酸红霉素片，薄膜衣片
英文名称: erythromycin, stearate (salt)；abboticine；bristamycin；dowmycin e；erypar；erythrocin stearate；erythromycin stearate；erythromycin stearic acid salt；erythromycin, octadecanoate (salt)
作用与用途
本品为大环内酯类抗生素，抗菌谱和青霉素相似，主要是对革兰阳性菌如金葡菌、溶血性链球菌、肺炎球菌、白喉杆菌、炭疽杆菌及梭形芽胞杆菌等，均有强大抗菌作用。对革兰阴性菌如脑膜炎双球菌、淋球菌、百日咳杆菌、流感杆菌、布氏杆菌、部分痢疾杆菌及大肠杆菌等有一定作用。特点是对青霉素产生耐药性的菌株，对本品敏感。作用机制主要是与核糖核蛋白体的50S亚单位相结合，抑制肽酰基转移酶，影响核糖核蛋白体的移位过程，妨碍肽链增长，抑制细菌蛋白质的合成，系抑菌剂。
临床上主要用于耐青霉素的金葡菌感染及对青霉素过敏的金葡菌感染。亦用于溶血性链球菌及肺炎球菌所致的呼吸道、军团菌肺炎、支原体肺炎、皮肤软组织等感染，此外，对白喉病人，以本品及白喉抗毒素联用则疗效显著。
剂量与用法
红霉素片(肠溶片)，口服，成人1g～2g/日；儿童每日30mg～50mg/kg，分3～4次。静注或静滴可用乳糖酸红霉素(Erythromycin Lactobionate)，成人1g～2g/日；儿童每日20mg～30mg/kg，分2～3次。
副作用
1 胃肠道反应，可有恶心、呕吐、腹痛及腹泻，反应与剂量大小有关。
2 过敏反应，可有荨麻疹及药物热。
3 可引起肝脏损害，如血清丙氨酸氨基转移酶升高，出现黄疸等。
4 静注或静滴乳糖酸红霉素可引起血栓性静脉炎，静注发生的可能性较多。肌注局部刺激性大，可引起疼痛及硬结，因此不宜肌注。
注意事项
1 本品在酸中不稳定，能被胃酸破坏，故需同时服用抑酸剂碳酸氢钠，如服用肠溶片则可避免。
2 乳糖酸红霉素应先以注射用水溶解，切不可用生理盐水或其它无机盐溶液溶解，因无机离子可引起沉淀。待溶解后则可用等渗葡萄糖注射液或生理盐水稀释供静滴，浓度不宜大于0.1%，以防血栓性静脉炎产生。
3 与碱化尿液药物碳酸氢钠同用时，本品在泌尿系统的抗菌活性随pH值的升高而增强。
4 本品与林可霉素和β 内酰胺类药物之间有拮抗作用，应避免联用。
5 乳糖酸红霉素与氨茶碱、辅酶A、细胞色素C、万古霉素、磺胺嘧啶钠、青霉素、氨苄青霉素钠、头孢噻吩钠及碳酸氢钠等混用可产生浑浊、沉淀或降效，故不宜同时静滴。
6 红霉素可抑制华法令和卡马西平在肝内代谢，增强两药的作用或毒性。与这两种药物合用时应注意观察。
7 红霉素可抑制茶碱代谢清除，提高其血浓度，这常发生在合用若干天以后。应注意监测。
包装规格：
250mg*100Tablets/Bottles
500mg*100Tablets/Bottles
生产厂家：美国阿伯制药公司
Erythrocin Stearate (Erythromycin Stearate)
Indications and Dosage
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERYTHROCIN STEARATE Filmtab tablets and other antibacterial drugs, ERYTHROCIN STEARATE Filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
ERYTHROCIN STEARATE tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes; Streptococcus pneumoniae; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)
Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae.
Listeriosis caused by Listeria monocytogenes.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Diphtheria: Infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma--In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythrocin® Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Primary syphilis caused by Treponema pallidum. Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy.
Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.
PROPHYLAXIS
Prevention of Initial Attacks of Rheumatic Fever-Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis).3 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days.
Prevention of Recurrent Attacks of Rheumatic Fever-Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).3
DOSAGE AND ADMINISTRATION
Optimal serum levels of erythromycin are reached when ERYTHROCIN STEARATE (erythromycin stearate) is taken in the fasting state or immediately before meals.
Adults: The usual dosage is 250 mg every 6 hours; or 500 mg every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.
Children: Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections this dosage may be doubled but should not exceed 4 g per day.
In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis), the therapeutic dosage of erythromycin should be administered for at least ten days.
The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides.3
Conjunctivitis of the newborn caused by Chlamydia trachomatis: Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks. 3
Pneumonia of infancy caused by Chlamydia trachomatis: Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.
Urogenital infections during pregnancy due to Chlamydia trachomatis: Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day or two erythromycin 333 mg tablets orally every 8 hours on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours, one 333 mg tablet orally every 8 hours or 250 mg by mouth four times a day should be used for at least 14 days. 5
For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis, when tetracycline is contraindicated or not tolerated: 500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least 7 days. 5
For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated: 500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least seven days. 5
Primary syphilis: 30 to 40 g given in divided doses over a period of 10 to 15 days.
Acute pelvic inflammatory disease caused by N. gonorrhoeae: 500 mg Erythrocin Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours, or 333 mg of erythromycin base orally every 8 hours for 7 days.
Intestinal amebiasis: Adults: 500 mg every 12 hours, 333 mg every 8 hours or 250 mg every 6 hours for 10 to 14 days. Children: 30 to 50 mg/kg/day in divided doses for 10 to 14 days.
Pertussis: Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.
Legionnaires' Disease: Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.
HOW SUPPLIED
ERYTHROCIN STEARATE Filmtab Tablets (erythromycin stearate tablets, USP) are supplied in the following strengths and packages.
ERYTHROCIN STEARATE Filmtab, 250 mg pink tablets imprinted with the corporate logo  and the Abbo-Code designation ES:
Bottles of 100..........(NDC 0074-6346-20)
Bottles of 500..........(NDC 0074-6346-53)
Bottles of 1000........(NDC 0074-6346-19)
ABBO-PAC® unit dose strip packages
of 100 tablets...........(NDC 0074-6346-38)
ERYTHROCIN STEARATE Filmtab, 500 mg pink tablets imprinted with the corporate logo  and the Abbo-Code designation ET:
Bottles of 100..........(NDC 0074-6316-13)
Recommended Storage: Store below 86°F (30°C).
http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=70569